A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies

Trial Profile

A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 24 Apr 2017

At a glance

  • Drugs Monalizumab (Primary)
  • Indications Carcinoma; Cervical cancer; Endometrial cancer; Fallopian tube cancer; Ovarian cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Apr 2017 Status changed from recruiting to active, no longer recruiting.
    • 02 Dec 2016 Results of dose ranging study (n=18) presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
    • 30 Nov 2016 According to an Innate Pharma media release, the cohort expansion part of this trial (up to 98 patients) is ongoing at the recommended Phase II dose (10 mg/kg) in patients with platinum sensitive ovarian cancer, platinum-resistant ovarian cancer, epithelial endometrial cancer and squamous cell carcinoma of the cervix.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top